NCT02581072

A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204

A Double-blind, Double-dummy, Randomized, 4-period Crossover Study to Define the ECG Effects of SB204 Using a Clinical and Supratherapeutic Dose Compared With Placebo and Moxifloxacin in Subjects With Acne Vulgaris: A Thorough ECG STudy

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 56 (actual)
• Sponsor: Novan, Inc. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

A Double-Blind, Double-Dummy, Randomized, 4-Period Crossover Study to Define the ECG Effects of SB204 Using a Clinical and Supratherapeutic Dose Compared with Placebo and Moxifloxacin (a Positive Control) in Subjects with Acne Vulgaris: A Thorough ECG Study

Detailed description

A Double-Blind, Double-Dummy, Randomized, 4-Period, Crossover Study to Define the ECG Effects of SB204 Using a Clinical and a Supratherapeutic Dose Compared with Placebo and Moxifloxacin (a Positive Control) in Subjects with Acne Vulgaris: A Thorough ECG Study

Conditions

• Acne Vulgaris

Interventions

Type	Name	Description
DRUG	SB204 4%	Applied topically once
DRUG	SB204 8% or 12%	Applied once topically
DRUG	Vehicle	Applied topically once

Timeline

• Start date: 2015-10-01
• Primary completion: 2015-12-01
• Completion: 2016-04-01
• First posted: 2015-10-20
• Last updated: 2018-11-19

Locations

1 site across 1 country: United States